Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.

Cucunawangsih C, Ansori ANM, Vatvani AD, Hariyanto TI

Open source

DOI
10.1080/14787210.2026.2636175
Published
2026 Feb
Container
Expert review of anti-infective therapy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14787210.2026.2636175,
  title = {Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.},
  author = {Cucunawangsih C and Ansori ANM and Vatvani AD and Hariyanto TI},
  year = {2026},
  journal = {Expert review of anti-infective therapy},
  doi = {10.1080/14787210.2026.2636175},
  url = {https://doi.org/10.1080/14787210.2026.2636175}
}

RIS

TY  - JOUR
TI  - Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.
AU  - Cucunawangsih C
AU  - Ansori ANM
AU  - Vatvani AD
AU  - Hariyanto TI
PY  - 2026
JO  - Expert review of anti-infective therapy
DO  - 10.1080/14787210.2026.2636175
UR  - https://doi.org/10.1080/14787210.2026.2636175
ER  - 

APA

C, C., ANM, A., AD, V., & TI, H. (2026). Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.. Expert review of anti-infective therapy. https://doi.org/10.1080/14787210.2026.2636175

Source records